Filing Details
Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) filed a Form 8-K with the Securities and Exchange Commission on October 20, 2026, disclosing a material event.
8k filedNASDAQ:QNRX
Quoin Pharmaceuticals Ltd. (QNRX) Reports Material Event to SEC
Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) filed a Form 8-K with the Securities and Exchange Commission on October 20, 2026, disclosing a material event.
At publication ·
What changed
Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Quoin Pharmaceuticals (QNRX) filed a Form 8-K on October 20, 2026, disclosing a material event to the SEC.
- The stock trades at $4.04 with a market capitalization of $6.5 million.
- The article does not specify what material event triggered the 8-K filing.
- 8-K filings typically report leadership changes, material agreements, acquisitions, or financial guidance changes.
Market Context
Quoin Pharmaceuticals Ltd.'s stock currently trades at $4.04 with a market capitalization of $6.5M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Quoin Pharmaceuticals Ltd.'s stock.
All SEC filings for Quoin Pharmaceuticals Ltd. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View QNRX Stock Page
Frequently Asked Questions
Where can I read QNRX's SEC filings?
Browse all filings on our QNRX SEC filings page.
What types of SEC filings does Quoin Pharmaceuticals Ltd. file?
Public companies like Quoin Pharmaceuticals Ltd. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
Loading related coverage…